CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation today announced that its Chief Executive Officer Frank Reynolds will be discussing breakthrough non-opiate pain treatments at the 2015 BIO Investor Forum held in San Francisco, CA this week.
PixarBio’s presentation:
| Date: | Tuesday, October 20, 2015 | ||||
| Time: |
10:00 AM PT |
||||
| Track: | Discovery | ||||
| Location: | Balboa Room | ||||
| Parc 55 San Francisco | |||||
| 55 Cyril Magnin Street, San Francisco, CA |
"Our non-opiate, non-addictive pain platform has developed into 18 patent pending products under R&D. Based on our Sept 2015 USFDA meeting we forecast first product approval in 2017 and as many as eight products USFDA approved by 2020. We're pumped plain & simple that we have the potential to eradicate clinic based addiction while quickly bringing products to market for knee, hip, and shoulder pain. The team is growing and integrating into a smoothly operating innovation engine," said PixarBio CEO Frank Reynolds.
The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One PartneringTM meetings.
About PixarBio Corporation
PixarBio Corporation is developing a targeted delivery platform to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. Cofounded by Frank Reynolds, MIT’s Dr. Robert S. Langer, Katrin Holzhaus, and Jason Criscione, PixarBio is focused on researching and developing targeted delivery systems for acute and chronic neurological conditions. For more information visit www.pixarbio.com.
Contacts
PixarBio Corporation
Katrin Holzhaus, 617-401-0041
Chief
Operating Officer
kholzhaus@pixarbio.com
